Trial Profile
A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Ocular inflammation; Scleritis
- Focus Therapeutic Use
- 16 Sep 2015 New trial record